Home  /  Resource Library  /  Sintilimab for relapsed/refractory classical Hodgkin’s lymphoma: Long-term follow-up on the multicenter, single-arm phase II ORIENT-1 study

Sintilimab for relapsed/refractory classical Hodgkin’s lymphoma: Long-term follow-up on the multicenter, single-arm phase II ORIENT-1 study

ASCO 2020: Results of a study examining Sintilimab for treatment of relapsed Hodgkin lymphoma.